These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 18520598)

  • 1. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    J Clin Pharm Ther; 2008 Feb; 33(1):67-73. PubMed ID: 18211619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
    Yamada S; Shiohira H; Yasui-Furukori N; Tateishi T; Akamine Y; Uno T
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1423-8. PubMed ID: 23435615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
    Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
    Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
    Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
    Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
    Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
    Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
    J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.
    Shiohira H; Yasui-Furukori N; Yamada S; Tateishi T; Akamine Y; Uno T
    Pharm Res; 2012 Aug; 29(8):2310-6. PubMed ID: 22549736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
    Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omeprazole disposition in children following single-dose administration.
    Kearns GL; Andersson T; James LP; Gaedigk A; Kraynak RA; Abdel-Rahman SM; Ramabadran K; van den Anker JN
    J Clin Pharmacol; 2003 Aug; 43(8):840-8. PubMed ID: 12953341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
    Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
    Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.